Dyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Dyne Therapeutics in a note issued to investors on Monday, May 6th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings of ($2.94) per share for the year. Chardan Capital has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.27) per share.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.17).

Several other brokerages have also recently issued reports on DYN. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Morgan Stanley assumed coverage on shares of Dyne Therapeutics in a research note on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price objective for the company. Oppenheimer reissued an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Stifel Nicolaus boosted their price objective on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Piper Sandler boosted their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $37.75.

Dyne Therapeutics Stock Down 2.3 %

Shares of NASDAQ DYN opened at $25.65 on Wednesday. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $30.27. The firm has a fifty day moving average of $26.47 and a 200-day moving average of $18.83. The stock has a market capitalization of $2.24 billion, a PE ratio of -6.46 and a beta of 1.00.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO Joshua T. Brumm sold 5,520 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $151,800.00. Following the transaction, the chief executive officer now owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Dyne Therapeutics news, CEO Joshua T. Brumm sold 5,520 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $151,800.00. Following the transaction, the chief executive officer now owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Mcneill sold 4,268 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $27.50, for a total transaction of $117,370.00. Following the completion of the transaction, the insider now owns 143,618 shares in the company, valued at approximately $3,949,495. The disclosure for this sale can be found here. Insiders have sold 1,875,432 shares of company stock worth $44,368,530 in the last quarter. 20.77% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently modified their holdings of the stock. Raymond James & Associates raised its stake in Dyne Therapeutics by 22.6% during the third quarter. Raymond James & Associates now owns 88,238 shares of the company’s stock valued at $791,000 after buying an additional 16,240 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Dyne Therapeutics by 4.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 157,443 shares of the company’s stock valued at $1,411,000 after acquiring an additional 7,196 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock valued at $75,000 after acquiring an additional 3,092 shares in the last quarter. TD Asset Management Inc acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at approximately $206,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Dyne Therapeutics by 95.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after acquiring an additional 4,552 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.